(NASDAQ: ADAG) Adagene's forecast annual revenue growth rate of 37.92% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Adagene's revenue in 2024 is $18,111,491.On average, 1 Wall Street analysts forecast ADAG's revenue for 2026 to be $2,177,709,182, with the lowest ADAG revenue forecast at $2,177,709,182, and the highest ADAG revenue forecast at $2,177,709,182. On average, 1 Wall Street analysts forecast ADAG's revenue for 2028 to be $2,602,883,601, with the lowest ADAG revenue forecast at $2,602,883,601, and the highest ADAG revenue forecast at $2,602,883,601.
In 2029, ADAG is forecast to generate $7,449,651,391 in revenue, with the lowest revenue forecast at $7,449,651,391 and the highest revenue forecast at $7,449,651,391.